Hassane M Zarour

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi Differential capacity of T cell priming in naive donors of promiscuous CD4+ T cell epitopes of HCV NS3 and Core proteins
    Florence A Castelli
    CEA, iBiTecS, Service d Ingénierie Moléculaire des Protéines, Gif sur Yvette, France
    Eur J Immunol 37:1513-23. 2007
  2. ncbi Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells
    H M Zarour
    Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Proc Natl Acad Sci U S A 97:400-5. 2000
  3. ncbi Melanoma vaccines: early progress and future promises
    Hassane M Zarour
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213, USA
    Semin Cutan Med Surg 22:68-75. 2003
  4. ncbi NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells
    Hassane M Zarour
    Department of Medicine and Melanoma Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213, USA
    Cancer Res 62:213-8. 2002
  5. ncbi NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells
    H M Zarour
    Department of Medicine and Melanoma Center, University of Pittsburgh Cancer Institute, Pennsylvania 15213, USA
    Cancer Res 60:4946-52. 2000
  6. ncbi One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma
    Maja Mandic
    Department of Medicine and The Melanoma Center, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Immunol 174:1751-9. 2005
  7. ncbi Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patients
    Pavol Kudela
    Department of Medicine and Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Immunol 179:7932-40. 2007
  8. ncbi Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1
    Pavol Kudela
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Immunol 186:312-22. 2011
  9. ncbi Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire
    Julien Fourcade
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213 2582, USA
    J Immunol 184:6709-18. 2010
  10. ncbi The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells
    Maja Mandic
    Department of Medicine and Melanoma Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Res 63:6506-15. 2003

Collaborators

Detail Information

Publications19

  1. ncbi Differential capacity of T cell priming in naive donors of promiscuous CD4+ T cell epitopes of HCV NS3 and Core proteins
    Florence A Castelli
    CEA, iBiTecS, Service d Ingénierie Moléculaire des Protéines, Gif sur Yvette, France
    Eur J Immunol 37:1513-23. 2007
    ..Interestingly, five of the most immunogenic peptides we identified correspond to frequently targeted T cell epitopes in infected patients...
  2. ncbi Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells
    H M Zarour
    Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Proc Natl Acad Sci U S A 97:400-5. 2000
    ..Taken together, these data support the use of this Melan-A/MART-1 DR4-restricted melanoma epitope in future immunotherapeutic trials designed to generate, augment, and quantitate specific CD4(+) T cell responses against melanoma in vivo...
  3. ncbi Melanoma vaccines: early progress and future promises
    Hassane M Zarour
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213, USA
    Semin Cutan Med Surg 22:68-75. 2003
    ....
  4. ncbi NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells
    Hassane M Zarour
    Department of Medicine and Melanoma Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213, USA
    Cancer Res 62:213-8. 2002
    ..They support the relevance of cancer vaccine trials with the NY-ESO-1 119-143 peptide in the large number of cancer patients with NY-ESO-1-expressing tumors...
  5. ncbi NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells
    H M Zarour
    Department of Medicine and Melanoma Center, University of Pittsburgh Cancer Institute, Pennsylvania 15213, USA
    Cancer Res 60:4946-52. 2000
    ....
  6. ncbi One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma
    Maja Mandic
    Department of Medicine and The Melanoma Center, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Immunol 174:1751-9. 2005
    ..They also support the relevance of cancer vaccine trials with peptides NY-ESO-1 87-111 in the large number of cancer patients with NY-ESO-1-expressing tumors...
  7. ncbi Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patients
    Pavol Kudela
    Department of Medicine and Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Immunol 179:7932-40. 2007
    ..Our findings have significant implications for the optimization of TCR gene transfer immunotherapies widely applicable to cancer patients...
  8. ncbi Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1
    Pavol Kudela
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Immunol 186:312-22. 2011
    ..Therefore, they provide a strong rationale for the inclusion of LAGE-1 peptides or protein in vaccine trials for patients with NY-ESO-1(+)/LAGE-1(+) tumors...
  9. ncbi Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire
    Julien Fourcade
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213 2582, USA
    J Immunol 184:6709-18. 2010
    ..They also suggest that TA-specific Treg expansion may be better impaired by therapies aimed at depleting CD4+CD25high Tregs and preventing the peripheral conversion of CD4+CD25- T cells...
  10. ncbi The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells
    Maja Mandic
    Department of Medicine and Melanoma Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Res 63:6506-15. 2003
    ....
  11. ncbi PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients
    Julien Fourcade
    Department of Medicine and Division of Hematology Oncology, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15213, USA
    J Immunol 182:5240-9. 2009
    ..They further support the use of PD-1/PD-L1 pathway blockade in cancer patients to partially restore NY-ESO-1-specific CD8(+) T cell numbers and functions, increasing the likelihood of tumor regression...
  12. ncbi Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients
    Julien Fourcade
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213 2582, USA
    J Immunother 31:781-91. 2008
    ..They also suggest that the presence of tumor-induced NY-ESO-1-specific T cells of well-defined clonotypes is critical for the expansion of tumor-reactive NY-ESO-1-specific CD8+ T cells after peptide-based vaccine strategies...
  13. ncbi CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1
    Julien Fourcade
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Cancer Res 72:887-96. 2012
    ..Collectively, our findings indicate that targeting BTLA along with the PD-1 and Tim-3 pathways is critical to reverse an important mechanism of immune escape in patients with advanced melanoma...
  14. ncbi Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers
    Bratislav Janjic
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Immunol 177:2717-27. 2006
    ..Because of its immunodominance, peptide TRAG-3(34-48) is of particular interest for the monitoring of spontaneous immune responses in patients with TRAG-3-expressing tumors and for the development of cancer vaccines...
  15. ncbi Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
    Julien Fourcade
    Department of Medicine and Division of Hematology Oncology, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15213, USA
    J Exp Med 207:2175-86. 2010
    ..Collectively, our findings support the use of Tim-3-Tim-3L blockade together with PD-1-PD-L1 blockade to reverse tumor-induced T cell exhaustion/dysfunction in patients with advanced melanoma...
  16. ncbi Next generation of immunotherapy for melanoma
    John M Kirkwood
    Hillman Cancer Center, Research Pavilion, Suite 1 32, 5117 Centre Ave, Pittsburgh, PA 15213 2584, USA
    J Clin Oncol 26:3445-55. 2008
    ..Immunotherapy has a long history with striking but limited success in patients with melanoma. To date, interleukin-2 and interferon-alfa2b are the only approved immunotherapeutic agents for melanoma in the United States...
  17. ncbi Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling
    Tatiana Raskovalova
    Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Cancer Res 67:5949-56. 2007
    ..Thus, blocking the inhibitory activity of tumor-produced adenosine might represent a new strategy for improvement of cancer immunotherapy...
  18. ncbi Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690
    John M Kirkwood
    Department of Medicine, University of Pittsburgh, Pennsylvania, USA
    Cancer 95:1101-12. 2002
    ....
  19. ncbi Absence of gamma-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell recognition of select immunodominant epitopes
    M Azizul Haque
    Department of Microbiology and Immunology, and the Walther Oncology Center, Indiana University School of Medicine, and the Walther Cancer Institute, Indianapolis, IN 46202, USA
    J Exp Med 195:1267-77. 2002
    ..Such disparities in the profile of antigenic epitopes displayed by tumors and bystander APCs may contribute to tumor cell survival in the face of immunological defenses...